Literature DB >> 32142168

Safety and efficacy of plasma exchange via direct femoral vein puncture in autoimmune blistering diseases.

Tadashi Yoshida1, Hitoshi Minakuchi1, Ryohei Takahashi1,2, Shinya Morita1,2, Mototsugu Oya1,2.   

Abstract

Plasma exchange (PE) is performed for patients with autoimmune blistering diseases by using multiple vascular access routes. We retrospectively examined the safety and the efficacy of PE using direct femoral vein puncture (FVP) technique, by comparing with that using double-lumen catheter (DLC). The troubles related to vascular route, such as catheter occlusion, insufficient blood flow and hematoma, were not different between the FVP group (4.6%) and the DLC group (6.7%), whereas access-related infections occurred more frequently in the DLC group (6.7%) than the FVP group (0.4%). Regarding the efficacy, the removal rate of autoantibodies in PE using the FVP technique was similar or lower, as compared with that using the DLC. These results suggest that PE with the FVP technique is able to be performed safely in patients with autoimmune blistering diseases, although the removal of autoantibodies is not superior to that using the DLC.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  pemphigoid; pemphigus; plasmapheresis; vascular access

Mesh:

Substances:

Year:  2020        PMID: 32142168     DOI: 10.1002/jca.21774

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  2 in total

1.  Successful Treatment of Anti-MDA5 Antibody-Positive Dermatomyositis-Associated Rapidly Progressive-Interstitial Lung Disease by Plasma Exchange: Two Case Reports.

Authors:  Rina Takahashi; Tadashi Yoshida; Kohkichi Morimoto; Yasushi Kondo; Jun Kikuchi; Shuntaro Saito; Sho Ishigaki; Yuko Kaneko; Tsutomu Takeuchi; Hiroshi Itoh; Mototsugu Oya
Journal:  Clin Med Insights Case Rep       Date:  2021-07-27

2.  Plasmapheresis: a feasible choice for bullous pemphigoid patients infected with SARS-CoV-2.

Authors:  Yu Cui; Caixia Hu; Yi Cheng; Xiaomei Han; Wenqing Wang
Journal:  Int J Dermatol       Date:  2021-09-14       Impact factor: 3.204

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.